1 / 36

HORIZONS AMI Trial

HORIZONS AMI Trial. A Prospective, Randomized Comparison of Bivalirudin vs. Heparin Plus Glycoprotein IIb/IIIa Inhibitors During Primary Angioplasty in Acute Myocardial Infarction – One Year Results – Roxana Mehran MD for the HORIZONS-AMI Investigators, TCT 2008. Background.

Download Presentation

HORIZONS AMI Trial

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. HORIZONS AMI Trial A Prospective, Randomized Comparison of Bivalirudin vs. Heparin Plus Glycoprotein IIb/IIIa Inhibitors During Primary Angioplasty in Acute Myocardial Infarction – One Year Results – Roxana Mehran MD for the HORIZONS-AMI Investigators, TCT 2008

  2. Background • Numerous studies have demonstrated a strong association between hemorrhagic complications and subsequent mortality in pts with ACS and after PCI • In the HORIZONS-AMI trial, among high risk pts with STEMI undergoing primary PCI, randomization to bivalirudin monotherapy compared to UFH + GPI resulted in reduced rates of bleeding, thrombocytopenia, and blood transfusions; non significantly different rates of reinfarction, stent thrombosis and TVR; and improved survival at 30 days • Whether these benefits are maintained at 1-year is unknown Mehran R, TCT 2008

  3. HORIZONS AMI 3,602 pts with STEMI with symptom onset ≤12 hours Aspirin, thienopyridine R 1:1 UFH + GP IIb/IIIa inhibitor (abciximab or eptifibatide) Bivalirudin monotherapy (± provisional GP IIb/IIIa) Emergent angiography, followed by triage to primary PCI, CABG or medical therapy 3006 pts eligible for stent randomization R 1:3 Paclitaxel-eluting TAXUS stent Bare metal EXPRESS stent Clinical FU at 30 days, 6 months, 1 year, and then yearly through 5 years Stone GW. NEJM 2008;358:2218-30.

  4. HORIZONS AMI 3,602 pts with STEMI with symptom onset ≤12 hours Aspirin, thienopyridine R 1:1 UFH + GP IIb/IIIa inhibitor (abciximab or eptifibatide) Bivalirudin monotherapy (± provisional GP IIb/IIIa) Pharmacology Arm Primary and Secondary Endpoints 1-Year Intention to Treat Population Outcomes in the 4 randomized groups Mehran R, TCT 2008

  5. Inclusion Criteria • STEMI >20 mins and <12 hours in duration • ST-segment elevation of 1 mm in 2 contiguous leads; or • Presumably new left bundle branch block; or • True posterior MI with ST depression of 1 mm in 2 contiguous anterior leads • Patients with cardiogenic shock, left main disease, etc., were not excluded • Age ≥18 years • Written, informed consent Stone GW. NEJM 2008;358:2218-30.

  6. Principal Exclusion Criteria • Contraindication to any of the study medications • Prior administration of thrombolytic therapy, bivalirudin, GP IIb/IIIa inhibitors, LMWH or fondaparinux for the present admission (prior UFH allowed) • Current use of coumadin • History of bleeding diathesis or known coagulopathy (including HIT), or will refuse blood transfusions • History of intracerebral mass, aneurysm, AVM, or hemorrhagic stroke; stroke or TIA within 6 months or any permanent neurologic deficit; GI or GU bleed within 2 months, or major surgery within 6 weeks; recent or known platelet count <100,000 cells/mm3 or hgb <10 g/dL • Planned elective surgical procedure that would necessitate interruption of thienopyridines during the first 6 months post enrollment Stone GW. NEJM 2008;358:2218-30.

  7. Study Medications (i) • Unfractionated heparin • 60 U/kg IV*; subsequent boluses titrated by nomogram to ACT 200-250 secs; terminated at procedure end unless prolonged antithrombin needed • Bivalirudin • Bolus 0.75 mg/kg IV**, infusion 1.75 mg/kg/h, not titrated to ACT; terminated at procedure end unless prolonged antithrombin needed (0.25 mg/kg/hr infusion) • Glycoprotein IIb/IIIa inhibitors • Routine use in UFH arm; recommended only for giant thrombus or refractory no reflow in bivalirudin arm • Abciximab or double bolus eptifibatide as per investigator discretion – dosing per FDA label, renal adjusted; continued for 12 (abcx) or 12-18 (eptif) * If pre randomization UFH administered, ACT is checked first ** If pre randomization UFH administered, started 30’ after last bolus Stone GW. NEJM 2008;358:2218-30.

  8. Study Medications (ii) • Aspirin • 324 mg chewed non enteric coated or 500 mg IV in the ER, followed by 300-325 mg/day in-hospital and 75-81 mg/day as out patient indefinitely • Thienopyridines • Clopidogrel 300 mg or 600 mg loading dose (per investigator discretion) in the ER followed by 75 mg PO QD for at least 6 months (1 year or longer recommended) • Ticlopidine load + daily dose permissible if clopidogrel is unavailable or patient is allergic • Other • Beta blockers: IV pre procedure followed by PO QD in the absence of contraindications; ACE inhibitors for HTN, CHF or LVEF <40%; Statin if LDL >100 mg/dl Stone GW. NEJM 2008;358:2218-30.

  9. 2 Primary Endpoints (at 30 Days) 1) Net Adverse Clinical Events and 2) Major Bleeding (non-CABG) • Intracranial bleeding • Intraocular bleeding • Retroperitoneal bleeding • Access site bleed requiring intervention/surgery • Hematoma ≥5 cm • Hgb  ≥3 g/dL with an overt source • Hgb  ≥4 g/dL w/o overt source • Reoperation for bleeding • Blood product transfusion Stone GW. NEJM 2008;358:2218-30.

  10. 2 Primary Endpoints (at 30 Days) 1) Net Adverse Clinical Events = 2) Major Bleeding (non-CABG) or Major adverse cardiovascular events (major secondary endpoint) • All-cause death • Reinfarction • Ischemic TVR • Stroke Stone GW. NEJM 2008;358:2218-30.

  11. Randomized 30 Day FU 1-Year FU Eligible 1-Year FU HORIZONS AMI 3602 pts with STEMI R 1:1 UFH + GP IIb/IIIa N=1802 Bivalirudin N=1800 N=1791 (99.4%) N=1787 (99.3%) • • • Not true MI* • • • 28 29 N=1774 N=1771 26 46 • • • Withdrew • • • • • • Lost to FU • • • 22 53 N=1702 (95.9%) N=1696 (95.8%) * Biomarkers WNL and no DS >50% by core lab determination → 30 day FU only Mehran R, TCT 2008

  12. Baseline Characteristics (i) * *P=0.04 Stone GW et al. NEJM 2008;358:2218-30

  13. Baseline Characteristics (ii) Stone GW et al. NEJM 2008;358:2218-30

  14. Study Drugs *97.7% and 7.5% during PCI. ** For giant thrombus or refractory no reflow after PCI. CCL = cardiac catheterization laboratory Stone GW. NEJM 2008;358:2218-30.

  15. Primary Management Strategy* UFH + GP IIb/IIIa Inhibitor N=1802 Bivalirudin Monotherapy N=1800 Primary PCI Deferred PCI CABG Medical Rx 2.1% 1.3% 0% 5.4% 5.3% 0.1% 92.5% 93.4% *Primary ITT analysis includes all pts regardless of treatment Stone GW. NEJM 2008;358:2218-30.

  16. Primary Endpoints at 30 Days Diff = -2.9% [-4.9, -0.8] RR = 0.76 [0.63, 0.92] PNI ≤ 0.0001 Psup = 0.005 Diff = -3.3% [-5.0, -1.6] RR = 0.60 [0.46, 0.77] PNI ≤ 0.0001 Psup ≤ 0.0001 Diff = 0.0% [-1.6, 1.5] RR = 0.99 [0.76, 1.30] Psup = 0.95 1 endpoint 1 endpoint Major 2 endpoint Stone GW et al. NEJM 2008;358:2218-30

  17. Aspirin and Thienopyridine Use Regular* aspirin use (%) Regular* thieno. use (%) Antiplatelet agent use (%) All P=NS All P=NS *Taken >50% of days since last visit Mehran R, TCT 2008

  18. Bivalirudin alone (n=1800) Heparin + GPIIb/IIIa (n=1802) 1-Year Net Adverse Clinical Events* 18.3% 15.7% Diff [95%CI] = -2.6% [-5.1, -0.1] HR [95%CI] = 0.84 [0.71, 0.98] P=0.03 NACE (%) Time in Months Number at risk Bivalirudin alone 1800 1559 1514 1483 1343 Heparin+GPIIb/IIIa 1802 1499 1459 1427 1281 • *MACE or major bleeding (non CABG) Mehran R, TCT 2008

  19. Bivalirudin alone (n=1800) Heparin + GPIIb/IIIa (n=1802) 1-Year Major Bleeding (non-CABG) 9.2% 5.8% Major Bleeding (%) Diff [95%CI] = -3.4% [-5.2, -1.7]2 HR [95%CI] = 0.61 [0.48, 0.78] P<0.0001 Time in Months Number at risk 1800 1621 1601 1586 1448 Bivalirudin alone 1802 1544 1532 1515 1368 Heparin+GPIIb/IIIa Mehran R, TCT 2008

  20. 1-Year Bleeding Endpoints* *Kaplan-Meier estimates; all CEC adjudicated, except protocol minor; **Primary endpoint; ***Life threatening Mehran R, TCT 2008

  21. Bivalirudin alone (n=1800) Heparin + GPIIb/IIIa (n=1802) 1-Year Major Adverse CV Events* 11.9% 11.9% Diff [95%CI] = 0.0% [-2.1, 2.2] HR [95%CI] = 1.00 [0.83, 1.21] P=0.98 MACE (%) Time in Months Number at risk Bivalirudin alone 1800 1627 1579 1544 1394 Heparin+GPIIb/IIIa 1802 1619 1573 1540 1380 • *MACE = All cause death, reinfarction, ischemic TVR or stroke Mehran R, TCT 2008

  22. Bivalirudin alone (n=1800) Heparin + GPIIb/IIIa (n=1802) 1-Year All-Cause Mortality 4.8% Δ = 1.4% 3.4% 3.1% Mortality (%) Diff [95%CI] = -1.5% [-2.8,-0.1] HR [95%CI] = 0.69 [0.50, 0.97] P=0.029 2.1% Δ = 1.0% P=0.049 Time in Months Number at risk 1800 1705 1684 1669 1520 Bivalirudin alone 1802 1678 1663 1646 1486 Heparin+GPIIb/IIIa Mehran R, TCT 2008

  23. Bivalirudin alone (n=1800) Heparin + GPIIb/IIIa (n=1802) 1-Year Mortality: Cardiac and Non Cardiac HR [95%CI] = 0.57 [0.38, 0.84] P=0.005 3.8% Δ = 1.7% 2.9% Cardiac Mortality (%) 2.1% Δ = 1.1% P=0.03 Non Cardiac 1.3% 1.1% Time in Months Number at risk Bivalirudin alone 1800 1705 1684 1669 1520 Heparin+GPIIb/IIIa 1802 1678 1663 1646 1486 Mehran R, TCT 2008

  24. Bivalirudin alone (n=1800) Heparin + GPIIb/IIIa (n=1802) 1-Year Death or Reinfarction 8.5% Δ = 1.9% 6.6% 4.5% Death or MI (%) HR [95%CI] = 0.77 [0.61, 0.98] P=0.04 3.8% Δ = 0.7% P=0.30 Time in Months Number at risk Bivalirudin alone 1800 1670 1638 1617 1469 Heparin+GPIIb/IIIa 1802 1648 1617 1593 1431 Mehran R, TCT 2008

  25. 1-Year MACE Components* *All Kaplan-Meier estimates, CEC adjudicated Mehran R, TCT 2008

  26. Adverse Events Between 30 Days and 1-Year *Kaplan-Meier estimates, landmark analysis, CEC adjudicated Mehran R, TCT 2008

  27. Bivalirudin alone (n=1611) Heparin + GPIIb/IIIa (n=1591) 1-Year Stent Thrombosis (ARC Definite/Probable) Δ = 0.3% 3.5% 3.2% 2.7% Stent Thrombosis (%) HR [95%CI] = 1.11 [0.76, 1.63] P=0.59 2.2% Δ = 0.5% P=0.31 Time in Months Number at risk Bivalirudin alone 1611 1525 1504 1486 1356 Heparin+GPIIb/IIIa 1591 1495 1475 1457 1315 Mehran R, TCT 2008

  28. 1-Year Stent Thrombosis* (N=3,202) *All Kaplan-Meier estimates except ≤24 hours; all CEC adjudicated Mehran R, TCT 2008

  29. R 3:1 R 3:1 HORIZONS AMI 3,602 pts with STEMI R 1:1 UFH + GP IIb/IIIa N=1802 Bivalirudin N=1800 Stent rand. eligible N=1479 N=1527 Stratified by 1st rand. TAXUS N=1111 EXPRESS N=368 TAXUS N=1146 EXPRESS N=381 Stone G, TCT 2008

  30. Interaction Between Drug and Stent Randomization 30 Day Pharmacology Endpoints (N=3006) • *MACE or major bleeding; **Protocol defined (non CABG); ***Death, reinfarction, stroke or ischemic TVR Mehran R, TCT 2008

  31. Interaction Between Drug and Stent Randomization 1-Year Stent Endpoints (N=3006) • *Death, reinfarction, stroke or stent thrombosis • **1081 lesions in the TAXUS group, 332 in the EXPRESS group Mehran R, TCT 2008

  32. Heparin + GPI / TAXUS (n=1111) Heparin + GPI / EXPRESS (n=368) Bivalirudin / TAXUS (n=1146) Bivalirudin / EXPRESS (n=381) 1-Year Mortality (All-Cause) 4.6% 4.0% 3.0% 2.6% Mortality (%) Pint=0.75 Time in Months Mehran R, TCT 2008

  33. Limitations • Open label design • Potential bias was mitigated by high protocol procedure compliance and use of blinded clinical event adjudication committees and core laboratories • Underpowered for low frequency safety endpoints and subgroup interactions • All such observations should be considered hypothesis-generating Mehran R, TCT 2008

  34. Conclusions • In this large scale, prospective, randomized trial of pts with STEMI undergoing a primary PCI management strategy, bivalirudin monotherapy compared to UFH plus the routine use of GP IIb/IIIa inhibitors resulted in: • A significant 16% reduction in the 1-year rate of composite net adverse clinical events • A significant 39% reduction in the 1-year rate of major bleeding Mehran R, TCT 2008

  35. Conclusions • In this large scale, prospective, randomized trial of pts with STEMI undergoing a primary PCI management strategy, bivalirudin monotherapy compared to UFH plus the routine use of GP IIb/IIIa inhibitors resulted in: • Significant 31% and 43% reductions in the 1-year rates of all-cause and cardiac mortality (absolute 1.4% and 1.7% reductions), with non significantly different rates of reinfarction, stent thrombosis, stroke and TVR at 1-year Mehran R, TCT 2008

  36. Clinical Implications • HORIZONS has demonstrated that the prevention of hemorrhagic complications after primary PCI in STEMI results in improved early and late survival • Optimal drug selection and technique to minimize bleeding are essential to enhance outcomes for pts undergoing interventional therapies Mehran R, TCT 2008

More Related